TLR8 and neutropenia: Lastly, although TLR8-GOF is not T-LGLL, the above-described similarities between the two disorders (e.g., neutropenia, LGL cells, a pro-inflammatory environment, and somatic activating mutations) suggest that bridge therapy with JAK/STAT inhibitors (e.g., tofacitinib) may work in other interface disorders with prominent LGL cell proliferation, such as T-LGL as well (32).